All In Biotech

Drug Trial Radar · NCT03622021

A Study of AK111 in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose-Escalation First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK111 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

68

Actual

Start

Aug 14, 2018

Primary completion

Sep 9, 2019

Study completion Sep 9, 2019

Sponsor

Lead sponsor
Akesobio Australia Pty LtdIndustry
Sponsor type
Industry
First posted
Aug 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized, double-blind, placebo-controlled, single dose-escalation first-in human study to evaluate the safety, tolerability, PK, PD and immunogenicity of AK111 in healthy subjects following SC administration. The study will consist of cohorts of healthy subjects. Cohort 1, four unique subjects will be randomized to receive either active AK111 (N=3) or matching placebo (N=1). Cohorts 2, 3, 4 and 5, eight unique subjects will be randomized to receive either active AK111 (N=6) or matching placebo (N=2). Approximately 36 subjects will be treated in this study.

Conditions

  • Psoriasis

Interventions

  • AK111 or PlaceboDrug

    All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent AE/SAEsTime frame: From baseline through 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Christchurch Clinical Studies Trust (CCST)

    Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.